Pure Global AI
NCT06395012Not yet recruiting

A First-In-Human Study of LY3985297 in Healthy Participants

A Phase 1, Randomized, Placebo-controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3985297 in Healthy Participants
Eli Lilly and CompanyPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Healthy
Drug/Device/Intervention
LY3985297
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Eli Lilly and Company
Location
Salt Lake City, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
May 01, 2024
End date
Jul 01, 2025
Enrollment
153 participants
Primary outcome

Number of participants with one or more Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration

Summary

The main purpose of this study is to see if LY3985297, the study drug, is safe and
 well-tolerated when given as a single dose or as multiple doses either through an intravenous
 (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study
 will also evaluate how much of the study drug LY3985297 gets into the blood stream and how
 long it takes the body to remove it.
 
 The study is conducted in two parts (part A and B), each part has a separate treatment
 cohort.
 
 The study will last up to approximately 116 days for part A, and 145 days for part B,
 including the screening period.

ICD-10 classifications
ObesitySeeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulHealthy person accompanying sick personLifestyle-related conditionMalnutrition
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06395012
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06395012 through Pure Global AI's free database. This Phase 1 trial is sponsored by Eli Lilly and Company and is currently Not yet recruiting. The study focuses on Healthy. Target enrollment is 153 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.